# ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

Study · id `cardio:ct-nct02619760` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02619760](<https://clinicaltrials.gov/study/NCT02619760>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02619760

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3045 participants.

## Technical summary

Registry record NCT02619760. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2018-12-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3045 participants (enrolled count; ClinicalTrials.gov record NCT02619760, source copy `cardio:ctgov-nct02619760-2024-06-14`, retrieved 2026-10-26)
- Started: 2015-12 (actual) (ClinicalTrials.gov record NCT02619760, source copy `cardio:ctgov-nct02619760-2024-06-14`, retrieved 2026-10-26)
- Primary completion: 2018-12-08 (actual) (ClinicalTrials.gov record NCT02619760, source copy `cardio:ctgov-nct02619760-2024-06-14`, retrieved 2026-10-26)
- Completion: 2023-12-31 (actual) (ClinicalTrials.gov record NCT02619760, source copy `cardio:ctgov-nct02619760-2024-06-14`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02619760, source copy `cardio:ctgov-nct02619760-2024-06-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02619760-2024-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study
- Acronym: STOPDAPT-2
- Condition: Coronary Artery Disease
- Intervention (Drug): 1-month DAPT
- Intervention (Drug): 12-month DAPT
- Lead sponsor: Kyoto University, Graduate School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Kyoto University, Graduate School of Medicine (`cardio:org-kyoto-university-graduate-school-of-medicine`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial (`cardio:pubmed-31237644`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial (`cardio:pubmed-32086787`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 82f8fbffe851133f5aab1e8eae60c8c3109fdea1cdf77505aab855848e6388c7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
